Submitted by Marlene Santos (marlene.bc.ufg@gmail.com) on 2016-10-13T17:13:38Z No. of bitstreams: 2 Dissertação Victor de Melo Caixeta - 2015.pdf: 2750656 bytes, checksum: c7c2c97e0c6537b3d17aa54409152ad3 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) / Approved for entry into archive by Jaqueline Silva (jtas29@gmail.com) on 2016-10-14T20:03:21Z (GMT) No. of bitstreams: 2 Dissertação Victor de Melo Caixeta - 2015.pdf: 2750656 bytes, checksum: c7c2c97e0c6537b3d17aa54409152ad3 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) / Made available in DSpace on 2016-10-14T20:03:21Z (GMT). No. of bitstreams: 2 Dissertação Victor de Melo Caixeta - 2015.pdf: 2750656 bytes, checksum: c7c2c97e0c6537b3d17aa54409152ad3 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Previous issue date: 2015-10-15 / Background: Corticobasal Degeneration (CBD) is an rare and heterogeneous disease in its presentations, representing an great diagnostic challenge. There aren´t, in Brasil, large CBD case series, and there aren´t many in the world as well. Its cognitive and behavioural aspects have received little (despite growing) attention. Objectives: To describe sociodemographic, clinic, neuropsychiatric, neuropathological, and neuroradiologic aspects in a large brazilian DCB case series. To perform a literature review on CBD, with special focus on cognitive and behavioural aspects. Methods: 70 patients data was collected, with CBD diagnosis according to the Cambridge criteria modified by Bak and Hodges (2011). The patients underwent clinical, neuropsychiatric, neuroradiologic (structural and functional) and pathologic (in six cases) retrospective analysis. There were studied clinical, sociodemographic, neuropsychiatric, neuroanatomic variables and family history. Results and Discussion: The mean age at onset was 62.8 years (sd=9,5), and both sexes were equally affected (52,9% male). Hemispheric asymmetry was present in 97% of cases, and the left brain hemisphere was the most affected (68,2% of cases). The most frequent initial presentation was “psychiatric” (with changes in behaviour and/or mood), present in 68,1% of cases, followed by motor-extrapyramidal presentation (54.3%). In the course of the disease, the predominant clinical form (phenotype) was the extrapyramidal-motor with 61.4% of cases, followed by "psychiatric" with 51.4%. There were five cases with presentation of Posterior Cortical Atrophy (PCA) In 37.7% there were not found classic CBD syndromes (e.g., alien hand syndrome). We found 18.7% of cases with family DCB, with four families presenting a phenotype not yet described, of CBD with NPH (Normal Pressure Hydrocephalus). We also observed cognitive and functional impairments in the evaluated scales (MMSE, Pfeffer and CDR), and frequent medical and psychiatric comorbidities, especially diabetes mellitus (23.5%), hypothyroidism (22.1%) and Bipolar Spectrum Disorders (46, 4%), the last two significantly more frequent in the sample. There were six cases of rapidly progressive DCB and six confirmed by autopsy CBD cases in the sample. Conclusion: We observed, in agreement with the literature, a wide variety of CBD presentations, including new and little described phenotypes (NPH and PCA). In the characterization of the sample, we observed a great prevalence and importance of cognitive, affective and behavioural presentations. / Introdução: A Degeneração Corticobasal (DCB), é uma doença rara e heterogênea em suas apresentações, representando um grande desafio diagnóstico. Não há descrições de grandes amostras de DCB no Brasil, e poucas no mundo. Seus aspectos cognitivos e comportamentais têm recebido pouca (apesar de crescente) atenção. Objetivos: Descrever aspectos sociodemográficos, clínicos, neuropsiquiátricos, neuropatológicos e de neuroimagem em uma grande série de casos brasileiros com DCB. Realizar uma revisão da literatura sobre a DCB, com especial enfoque em aspectos cognitivos e comportamentais. Metodologia: Foram colhidos dados de 70 pacientes com DCB de acordo com critérios de Cambridge modificados por Bak e Hodges (2011). Os pacientes foram submetidos à avaliação retrospectiva clínica e neuropsiquiátrica, de neuroimagem estrutural e funcional e seis pacientes ao exame neuropatológico. Foram estudadas variáveis sociodemográficas, clínicas, neuropsiquiátricas, neuroanatômicas, e antecedentes familiares. Resultados e Discussão: A idade média de início dos sintomas foi de 62,8 anos (dp=9,5), sendo os dois sexos igualmente afetados (52,9% masculino). Assimetria hemisférica esteve presente em 97% dos casos e o hemisfério esquerdo foi o mais acometido (68,2% dos casos). A apresentação inicial mais freqüente foi a “psiquiátrica” (com alterações do comportamento e/ou humor), presente em 68,1% dos casos, seguida da apresentação motora-extrapiramidal (54,3%). No decorrer da doença, a forma clínica (fenótipo) predominante foi a motora-extrapiramidal, com 61,4% dos casos, seguida da “psiquiátrica”, com 51,4%. Houve cinco casos com apresentação de Atrofia Cortical Posterior (ACP). Em 37,7% não ocorreram achados clássicos da DCB (por exemplo, síndrome da mão estrangeira). Encontramos 18,7% de casos com DCB familiar, com quatro famílias apresentando um fenótipo ainda não descrito, de DCB com HPN (Hidrocefalia de Pressão Normal). Observamos também prejuízos cognitivos e funcionais nas escalas avaliadas (MEEM, Pfeffer e CDR), e comorbidades clínicas e psiquiátricas frequentes, em especial Diabetes Mellitus (23,5%), hipotireoidismo (22,1%) e Transtornos do Espectro Bipolar (46,4%), os dois últimos com frequência na amostra significativamente maior que na população. Houve seis casos de DCB rapidamente progressiva e seis casos confirmados por necropsia na amostra. Conclusão: Observamos, em consenso com a literatura, uma grande variedade de apresentações da DCB, inclusive com formas novas e pouco descritas (HPN e ACP). Na caracterização da amostra, percebemos grande frequência e importância das apresentações comportamentais, afetivas e cognitivas.

Submitted by JÚLIO HEBER SILVA (julioheber@yahoo.com.br) on 2016-12-12T17:52:54Z No. of bitstreams: 2 Dissertação - George Martins Ney da Silva Júnior - 2015.pdf: 2151149 bytes, checksum: 266f50dd135504e70740809576b490bf (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) / Approved for entry into archive by Jaqueline Silva (jtas29@gmail.com) on 2016-12-13T19:31:57Z (GMT) No. of bitstreams: 2 Dissertação - George Martins Ney da Silva Júnior - 2015.pdf: 2151149 bytes, checksum: 266f50dd135504e70740809576b490bf (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) / Made available in DSpace on 2016-12-13T19:31:57Z (GMT). No. of bitstreams: 2 Dissertação - George Martins Ney da Silva Júnior - 2015.pdf: 2151149 bytes, checksum: 266f50dd135504e70740809576b490bf (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Previous issue date: 2015-08-04 / Background: this study aimed to contribute to the knowledge of the interrelation of two morbid conditions that affect the autonomy and independence of the elderly: Bipolar disorder (BD) and the dementias. Methods: the medical records were reviewed to meet criteria at the same time for BD and dementia, resulting in a database of 130 cases (n = 130). Their demographics characteristics were described, as well as the frequencies of the diagnoses of dementia subtypes, their correlations with the age of dementia, the age of initiation of BD, its clinical forms and psychopathologic presentation. It was also studied the impact when the DSM4-TR diagnostic criteria was shifted to the Akiskal criteria for BD. Results: in the sample, the predominant dementia age range was senile dementia (senile: 85.71%; presenile: 14.29%) and the most common dementia subtypes were Corticobasal degeneration (CBD: 24.62%) and the Fronto-Temporal Lobar Degeneration (FTLD: 19.23%). The age of initiation of BD starting 35 years old or over amounted to 74.78% (between 10 and 34 years: 25.22%; between 35 and 59 years: 36.52%; and ≥ 60 years: 38.26%), with the following clinical forms of BD present in the sample: BD1: 71.54%, BD2: 20.77%; and Cyclothymia: 7.69%. The psychopathologic clinical presentation of BD prevalent in the sample was Mixed Episodes (38.46%), followed by Mania (33.07%), Hypomania with major depression (20.77%) and Hypomania without major depression (7.7%). When applied diagnostic criteria of Akiskal, the clinical form of BD prevalent in the sample remained the BD1 (46.92%), followed by the BD6 (34.62%) and the BD2 (18.46%). Conclusions: the results showed that the CBD and FTLD were the most common dementia in comorbidity with BD. And that the BD, in such cases, was predominantly late (≥ 35 years) or very late (≥ 60 years) and in its most severe form (BD1), with the most common psychopathologic syndrome of Mixed State or Mania, suggesting that the CBD and FTLD should be actively searched in the follow-up of these cases. DCB and DLFT in comorbidity to BD offer a privileged field of research for the pathophysiology of dementia and TB itself. / Introdução: O presente estudo teve como objetivo contribuir para o conhecimento da inter-relação de duas condições mórbidas que afetam a autonomia e a independência dos idosos: o Transtorno Bipolar (TB) e as demências. Métodos: Foram revistos os prontuários que preenchiam critérios concomitantemente para TB e demência, resultando num banco de dados de 130 casos. Foram descritas as suas caraterísticas sociodemográficas, as frequências dos diagnósticos dos subtipos de demência e suas correlações com: a faixa etária da demência; a faixa etária de início do TB, suas formas clínicas e apresentação psicopatológica. Foi também estudado se a mudança de critérios diagnósticos do DSM4-TR para os de Akiskal impactaria nos resultados. Resultados: Na amostra (n=130), a faixa etária predominante da demência foi a senil (senil: 85,71%; pré-senil:14,29%) e os tipos de demência mais frequentes foram a Degeneração Corticobasal (DCB: 24,62%) e a Degeneração Lobar Fronto-Temporal (DLFT: 19,23%). A faixa etária de início do TB acima dos 35 anos ocorreu em 74,78% (entre 10 e 34 anos: 25,22%; entre 35 e 59 anos: 36,52%; e≥60 anos: 38,26%), com as seguintes formas clínicas de TB presentes na amostra: TB1: 71,54%, TB2: 20,77% e Ciclotimia: 7,69%. A configuração psicopatológica de apresentação clínica do TB predominante na amostra foi a de Episódios Mistos (38,46%), seguida por Mania (33,07%), Hipomania com Depressão Maior (20,77%) e Hipomania sem Depressão Maior (7,7%). Quando aplicados os critérios diagnósticos de Akiskal, a forma clínica de TB predominante na amostra permaneceu o TB1 (46,92%), seguido pelo TB6 (34,62%) e o TB2 (18,46%). Conclusões: Os resultados mostraram que a DCB e a DLFT foram as demências mais frequentes em comorbidade com o TB. E que o TB, nesses casos, foi predominantemente de início tardio (≥35 anos) ou muito tardio (≥60 anos) e em sua forma mais grave (TB1), tendo como síndrome psicopatológica mais frequente o Episódio Misto ou a Mania, sugerindo que a DCB e a DLFT sejam pesquisadas ativamente ao longo de seu seguimento. DCB e DLFT comórbidas ao TB oferecem um campo privilegiado de pesquisas para a fisiopatologia das demências e do próprio TB.

The pre-symptomatic stage of neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD) occurs several decades before the clinical onset. Changes in the lysosomal network, i.e. the autophagosomal, endosomal and lysosomal vesicular system, are among the first alterations observed. There are currently no treatments to slow or cure neurodegenerative diseases, and there is a great need for discovery of treatment targets in cellular pathways where pathology pre-dates the neuronal death. It is also crucial to be able to diagnose neurodegenerative diseases earlier, both to enable early intervention treatment and aid in selecting clinical trial populations before the patient has widespread pathology. This thesis aims at investigating the potential of lysosomal network proteins as biomarkers and therapeutic targets in neurodegenerative disease. A targeted search for lysosomal network proteins was performed in cerebrospinal fluid (CSF) from AD patients, and seven proteins: early endosomal antigen 1 (EEA1), lysosomal-associated membrane proteins 1 and 2 (LAMP-1, LAMP-2), lysozyme, microtubule-associated protein 1 light chain 3 (LC3), Rab3 and Rab7, were elevated. The levels of EEA1, LAMP-1, LAMP-2, LC3, lysozyme and Rab3 were also measured in CSF from parkinsonian syndrome patients: PD, clinically diagnosed 4-repeat tauopathy, pathologically confirmed corticobasal degeneration (CBD) and pathologically confirmed progressive supranuclear palsy (PSP) patients. LAMP-1 and LAMP-2 were decreased in PD. LC3 and lysozyme levels were increased in 4-repeat tauopathy patients. EEA1 was decreased and lysozyme increased in PSP, and LAMP-1, LAMP-2, LC3 and lysozyme were increased in CBD. The lysosomal network proteins had different CSF protein profiles in all the parkinsonian syndromes, as well as in AD. It should be emphasized that only a select few of the lysosomal network proteins were observed to be changed, rather than a general change in lysosomal network proteins, which implicates the involvement of these seven proteins in specific pathological processes. The most interesting candidates, LAMP-2 and lysozyme, were selected for further study for their involvement in the pathology of AD. Lysozyme was found to co-localise with Aβ plaques in AD patients and overexpression prolonged survival and improved the activity in a Drosophila model of AD. Lysozyme was found to alter the aggregation pathway of Aβ1-42, to counteract the formation of toxic Aβ species and to protect from Aβ1-42 induced cell toxicity. Aβ1-42 in turn was found to increase the expression of lysozyme in both neuronal and glial cells. These data suggest that lysozyme levels rise in AD as a compensatory response which is protective against Aβ associated toxicity. LAMP-2 mRNA and protein were found increased in brain areas relevant for AD pathology and various cellular models showed complex involvement of LAMP-2 in Aβ related pathology, with extensive crosstalk between LAMP-2 and Aβ. Exposure to oligomeric Aβ1-42 caused an upregulation of LAMP-2 and in turn, overexpression of LAMP-2 caused a reduction in secreted levels of Aβ1-42, as well as changing the generation pattern of Aβ and affecting clearance and secretion of Aβ1-42. These data indicate that the increased levels of LAMP-2 in AD could be an attempt to regulate Aβ generation and secretion. In summary, this thesis reports that utilising lysosomal network proteins as biomarkers and novel therapeutic targets for neurodegenerative diseases holds great promise.

Hyperfosforylering av biomarkörproteinet Tau förekommer i flera neurodegenerativa sjukdomar som kallas Taupathies. Proteinets huvudfunktion i människokroppen är att modulera flexibilitet och stabilitet för axonal-mikrotubulin. I Taupathies utlöser hyperfosforyleringen av Tau instabilitet och neurodegenerationen. I dagens läge kan hyperfosforylering av treonin 217 (P217) endast mätas i hjärnan. I den här studien undersöks hyperfosforyleringen av treonin 217 (P217). I syfte att se om nivåerna av P217 är mätbara i cerebrospinalvätska (CSV) och i blodet. Samt för att evaluera hur nivåer av P217 förändras i olika Taupathies, genom att testa hjärnprover från friska kontroller och olika Taupathies. Studien görs för att öka kunskapen om effekten av hyperfosforylering av treonin 217 i Taupathies och för att bidra med en ny provtagningsmetod för P217. Simoa HD-1 Analyzer var instrumentet som användes för analyserna av P217. Det är ett instrument som kan upptäcka onormala nivåer av biomarkörer genom kvantifiering, med hjälp av antikroppar och ett enzym. Enzymet kallas Streptavidin β-galaktosidas och omvandlar en befintlig P217-molekyl i proven till en fluorescerande produkt. Genom Simoa HD-1 Analyzer utvecklades en ultrasensitiv analys med antikropparna P217 och Tau 12, som kunde upptäcka mycket låga nivåer av P217 i hjärnan, CSF och i blod. Förändring av P217-nivåer hittades även i olika Taupathies. De Taupathies med de högsta nivåerna av P217 var Progressiv supranukleär pares, Corticobasal degeneration och Globular glial Taupathies. / Hyperphosphorylation of the biomarker protein Tau occurs in many neurodegenerative diseases called Taupathies. The proteins main function in the human body is to modulate flexibility and stability for axonal microtubules. In Taupathies the hyperphosphorylation of the Tau triggers instability and neurodegeneration. Nowdays hyperphoshorylation on threonine 217 (P217) can only be measured in the brain. In this study the hyperphoshorylation on the phosphorylation site of threonine 217 (P217) is examined. In aim to see if levels of P217 is measurable in cerebrospinal fluid (CSF) and in blood. As well to evaluate how P217 variate in different Taupathies, through the use of brain samples from healthy controls and different Taupathies. The study is made for the purpose of enhancing the pure knowledge about the effect of hyperphosphorylation on threonine 217 in Taupathies and to contribute with a new sampling method for P217. Simoa HD-1 Analyzer was the key instrument of the analyses of P217. It’s an instrument which can detect abnormal levels of biomarkers through quantification, with help of antibodies and an enzyme. The enzyme is called Streptavidin β-galactosidase and converts an existing P217 molecule in the samples to a fluoresce product. Through the use of Simoa HD-1 Analyzer an ultrasensitive assay with antibodies P217 and Tau 12 was developed which could detect very low levels of P217 in brain, CSF and in blood. Variation of P217 levels was also found in different Taupathies. The Taupathies with the highest levels of P217 was Progressive supranuclear palsy, Corticobasal Degeneration and Globular glial Taupathies.

In dieser Arbeit kann gezeigt warden, dass mit der kortiko-muskulären und intermuskulären Frequenzanalyse distinkte Koheränzmuster bei verschiedenen Bewegungsstörungen (kortikaler Myoklonus, Extremitätendystonie, Myoklonus bei kortikobasaler Degeneration) identifiziert werden können. Ferner konnte gezeigt werden, dass das retikulospinale System mit der intermuskulären Frequenzanalyse untersucht werden kann, was neue Perspektiven bei der Untersuchung subkortikaler Abschnitte des motorischen Systems ermöglicht. / It can be shown in this work that distinct patterns of cortico-muscular and/or intermuscular coherence can be identfied in a variety of movement disorders (cortical myoclonus, limb dystonia, myoclonus of CBD). Additionally, it could be demonstrated that the assessment of the reticulospinal system is feasible by using intermuscular frequency analysis of homologous muscles, which might open up a new line of research of subcortical drives within the motor system.